Novel NFKBIA variant causing autosomal ectodermal dysplasia with immunodeficiency
Corresponding Author
Pablo López Sanz
Department of Dermatology, Hospital General Universitario de Albacete, Albacete, Spain
Correspondence
Pablo López Sanz, Department of Dermatology, Hospital General Universitario de Albacete, C/Hermanos Falcó N37, Albacete 02006, Castilla-La Mancha, Spain.
Email: [email protected]
Carla Gianelli, Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Carla Gianelli
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Correspondence
Pablo López Sanz, Department of Dermatology, Hospital General Universitario de Albacete, C/Hermanos Falcó N37, Albacete 02006, Castilla-La Mancha, Spain.
Email: [email protected]
Carla Gianelli, Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.
Email: [email protected]
Search for more papers by this authorCarlos Zozaya Nieto
Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorEsperanza Escribano Palomino
Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorLucía del Pino Molina
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorRebeca Rodríguez Pena
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorLaura Miguel Berenguel
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorBrenda Sánchez Garrido
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorTristán Gabriel Sobral Costas
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorRaúl de Lucas Laguna
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorElena Ruiz
Department of Pathology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorCarmen Cámara Hijón
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorEduardo López-Granados
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorMaría Bravo García-Morato
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorMarta Feito Rodríguez
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorCorresponding Author
Pablo López Sanz
Department of Dermatology, Hospital General Universitario de Albacete, Albacete, Spain
Correspondence
Pablo López Sanz, Department of Dermatology, Hospital General Universitario de Albacete, C/Hermanos Falcó N37, Albacete 02006, Castilla-La Mancha, Spain.
Email: [email protected]
Carla Gianelli, Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Carla Gianelli
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Correspondence
Pablo López Sanz, Department of Dermatology, Hospital General Universitario de Albacete, C/Hermanos Falcó N37, Albacete 02006, Castilla-La Mancha, Spain.
Email: [email protected]
Carla Gianelli, Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.
Email: [email protected]
Search for more papers by this authorCarlos Zozaya Nieto
Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorEsperanza Escribano Palomino
Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorLucía del Pino Molina
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorRebeca Rodríguez Pena
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorLaura Miguel Berenguel
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorBrenda Sánchez Garrido
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorTristán Gabriel Sobral Costas
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorRaúl de Lucas Laguna
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorElena Ruiz
Department of Pathology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorCarmen Cámara Hijón
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorEduardo López-Granados
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorMaría Bravo García-Morato
Department of Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Rare Diseases Network Research Center (CIBERER U767), Clinical Immunology, Hospital Universitario La Paz, Madrid, Spain
Clinical Immunology, Hospital Universitario La Paz, Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Search for more papers by this authorMarta Feito Rodríguez
Department of Pediatric Dermatology, Hospital Universitario La Paz, Madrid, Spain
Search for more papers by this authorPablo López Sanz, Carla Gianelli, María Bravo García-Morato and Marta Feito Rodríguez contributed equally to this article.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Boisson B, Puel A, Picard C, Casanova JL. Human IkappaBalpha gain of function: a severe and syndromic immunodeficiency. J Clin Immunol. 2017; 37(5): 397–412.
- 2Batlle-Maso L, Mensa-Vilaro A, Solis-Moruno M, Marques-Bonet T, Arostegui JI, Casals F. Genetic diagnosis of autoinflammatory disease patients using clinical exome sequencing. Eur J Med Genet. 2020; 63(5):103920.
- 3Gunderman LM, Asano T, Casanova JL, Boisson B, Khojah A. Novel NF-kappa B inhibitor alpha gain-of-function variant in an infant with lymphocytosis and recurrent Serratia bacteremia. J Clin Immunol. 2023; 43(6): 1122–1126.
- 4Chear CT, El Farran BAK, Sham M, Ramalingam K, Noh LM, Ismail IH, et al. A novel De novo NFKBIA missense mutation associated to ectodermal dysplasia with Dysgammaglobulinemia. Genes (Basel). 2022; 13(10):1900.
- 5Janssen R, van Wengen A, Hoeve MA, ten Dam M, van der Burg M, van Dongen J, et al. The same IkappaBalpha mutation in two related individuals leads to completely different clinical syndromes. J Exp Med. 2004; 200(5): 559–568.
- 6Sogkas G, Adriawan IR, Ringshausen FC, Baumann U, Schroder C, Klemann C, et al. A novel NFKBIA variant substituting serine 36 of IkappaBalpha causes immunodeficiency with warts, bronchiectasis and juvenile rheumatoid arthritis in the absence of ectodermal dysplasia. Clin Immunol. 2020; 210:108269.
- 7Conti F, Carsetti R, Casanova JL, Fischer A, Cancrini C. A 23-year follow-up of a patient with gain-of-function IkB-alpha mutation and stable full Chimerism after hematopoietic stem cell transplantation. J Clin Immunol. 2020; 40(6): 927–933.
- 8Lorenzini T, Fliegauf M, Klammer N, Frede N, Proietti M, Bulashevska A, et al. Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. J Allergy Clin Immunol. 2020; 146(4): 901–911.
- 9Moghaddas F, Masters SL. Monogenic autoinflammatory diseases: Cytokinopathies. Cytokine. 2015; 74(2): 237–246.
- 10Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021; 19(1): 135.
Online Version of Record before inclusion in an issue
